Most patients with low-risk differentiated thyroid cancer can avoid postoperative radioiodine without increasing their 5-year recurrence risk, a new phase 3 trial finds. Medscape Medical News
Most patients with low-risk differentiated thyroid cancer can avoid postoperative radioiodine without increasing their 5-year recurrence risk, a new phase 3 trial finds. Medscape Medical News